NDC Package 55513-164-01 Kanjinti

Trastuzumab-anns Kit - View Billable Units, 11-Digit Format, RxNorm

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
55513-164-01
Package Description:
1 KIT in 1 CARTON * 1 VIAL, MULTI-DOSE in 1 CARTON (55513-132-01) / 20 mL in 1 VIAL, MULTI-DOSE * 20 mL in 1 VIAL (55513-152-01)
Product Code:
Proprietary Name:
Kanjinti
Non-Proprietary Name:
Trastuzumab-anns
Usage Information:
Trastuzumab is used to treat certain breast or stomach cancers that produce more than the normal amount of a certain substance called HER2 protein. Trastuzumab belongs to a class of medications known as monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. This monograph is about the following trastuzumab products: trastuzumab, trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp.
11-Digit NDC Billing Format:
55513016401
Billing Unit:
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
NDC to RxNorm Crosswalk:
  • RxCUI: 2174804 - trastuzumab-anns 420 MG in 20 mL Injectable Solution
  • RxCUI: 2174804 - trastuzumab-anns 21 MG/ML Injectable Solution
  • RxCUI: 2174804 - trastuzumab-anns 420 MG per 20 ML Injectable Solution
  • RxCUI: 2174809 - KANJINTI 420 MG in 20 mL Injectable Solution
  • RxCUI: 2174809 - trastuzumab-anns 21 MG/ML Injectable Solution [Kanjinti]
  • Product Type:
    Human Prescription Drug
    Labeler Name:
    Amgen Inc
    Dosage Form:
    Kit - A packaged collection of related material.
    Sample Package:
    No
    FDA Application Number:
    BLA761073
    Marketing Category:
    BLA - A product marketed under an approved Biologic License Application.
    Start Marketing Date:
    02-01-2023
    Listing Expiration Date:
    12-31-2025
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 55513-164-01?

    The NDC Packaged Code 55513-164-01 is assigned to a package of 1 kit in 1 carton * 1 vial, multi-dose in 1 carton (55513-132-01) / 20 ml in 1 vial, multi-dose * 20 ml in 1 vial (55513-152-01) of Kanjinti, a human prescription drug labeled by Amgen Inc. The product's dosage form is kit and is administered via form.

    Is NDC 55513-164 included in the NDC Directory?

    Yes, Kanjinti with product code 55513-164 is active and included in the NDC Directory. The product was first marketed by Amgen Inc on February 01, 2023 and its listing in the NDC Directory is set to expire on December 31, 2025 if the product is not updated or renewed by the manufacturer.

    What is the NDC billing unit for package 55513-164-01?

    The contents of this package are billed per "each", products billed on a per each basis are usually products dispensed in discreet units.

    What is the 11-digit format for NDC 55513-164-01?

    The 11-digit format is 55513016401. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-3-255513-164-015-4-255513-0164-01